Janiczek Wealth Management’s Nektar Therapeutics NKTR Stock Holding History

Janiczek Wealth Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-7	Closed	–	–	1065
2022 Q3	$0	Buy	+7	New	+$416	﹤0.01%	1022

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Janiczek Wealth Management's NKTR Position: Q4 2022 in Review

Janiczek Wealth Management sold out of Nektar Therapeutics (NKTR) in Q4 2022, closing a stake of 7 shares.

Janiczek Wealth Management first reported a position in NKTR in Q3 2022 and held it in 1 quarter. The position peaked at $0 in Q3 2022. 214 funds tracked by Wall St. Rank hold NKTR as of Q4 2022.

Janiczek Wealth Management reported no remaining Nektar Therapeutics position as of Q4 2022 after selling out during the quarter.
Janiczek Wealth Management sold 7 Nektar Therapeutics shares in Q4 2022.
Janiczek Wealth Management first reported a position in Nektar Therapeutics in Q3 2022 and held it in 1 quarter.
Janiczek Wealth Management's Nektar Therapeutics position peaked at $0 in Q3 2022.
214 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2022.

Based on Janiczek Wealth Management's 13F filing for Q4 2022, filed 23 Jan 2023.